Topiramate in medically intractable partial epilepsies: Double-blind placebo-controlled randomized parallel group trial

Epilepsia

Volumn 40, Issue 12, 1999, Pages 1767-1774

  Lee, B I ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Adverse events; Efficacy; Median seizure frequency reduction rate (MSFRR); Responder rate; Topiramate

Indexed keywords

TOPIRAMATE;

ABDOMINAL PAIN; ADULT; ANOREXIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INTRACTABLE EPILEPSY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT SELECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEIZURE THRESHOLD;

EID: 0032786707     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1157.1999.tb01596.x     Document Type: Article

References (13)

1. Coulter DA, Sombati S, De Lorenzo R. Selective effects of topiramate on sustained repetitive firing and spontaneous bursting in cultured hippocampal neurons. Epilepsia 1993;34(suppl 2):123.
2. White HS, Brown SD, Skeen GA, Twyman RE. The investigational anticonvulsant topiramate potentiates GABA-evoked currents in mouse cortical neurons. Epilepsia 1995;36(suppl 4):34.
3. Severt L, Coulter DA, Sombati S, De Lorenzo RJJ. Topiramate selectively blocks kainate currents in cultured hippocampal neurons. Epilepsia 1995;36(suppl 4):38.
4. Perucca E. A pharmacological and clinical review on topiramate, a new antiepileptic drug. Pharmacol Res 1997;35:241-56.
5. Privitera M, Fincham R, Penry J, et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600, 800 and 1000 mg daily dosage. Neurology 1996;46:1678-83.
6. Faught E, Wilder BJ, Ramsay RE, et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200, 400, and 600 mg daily dosages. Neurology 1996;46:1684-90.
7. Tassinari CA, Michelucci R, Chauvel P, et al. Double-blind placebo-controlled trial of topiramate (600 mg daily) for thetreatment of refractory partial epilepsy. Epilepsia 1996;37:763-8.
8. Sharief M, Viteri C, Ben-Menachem E, Weber M, Reife R, Pledger G. Double blind, placebo-controlled study in patients with refractory partial epilepsy. Epilepsy Res 1996;25:217-24.
9. Pledger G, Reife RA, Lim P. Topiraraate: intent-to-treat and other analysis. Epilepsia 1996;37(suppl 4):72.
10. Shorvon SD. Safety of topiramate: adverse events and relationships to dosing. Epilepsia 1996;37(suppl 2):18-22.
11. Florey CV. Sample size for beginners. BMJ 1993;306: 1181-4.
12. Reife RA. Pledger G, Lim P, Karim R. Topiramate as adjunctive therapy in refractory epilepsy: pooled analysis of data from five double-blind, placebo-controlled trials. Epilepsia 1997;38(suppl 1):S31-3.
13. Seino M, Naryti S, Ito T, Miyazaki H. Other antiepileptic drugs: zonisamide. In: Levy RH. Mattson RH, Meldrum BS, eds. Antiepileptic drugs. 4th ed. New York: Raven Press, 1995:1011-23.